Free Trial
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Y-mAbs Therapeutics logo
$4.41 -0.10 (-2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.42 +0.00 (+0.11%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Key Stats

Today's Range
$4.40
$4.62
50-Day Range
$3.64
$5.27
52-Week Range
$3.55
$16.11
Volume
113,050 shs
Average Volume
299,267 shs
Market Capitalization
$199.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.60
Consensus Rating
Moderate Buy

Company Overview

Y-mAbs Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

YMAB MarketRank™: 

Y-mAbs Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 459th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Y-mAbs Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, no hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Y-mAbs Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Y-mAbs Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Y-mAbs Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Y-mAbs Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Y-mAbs Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Y-mAbs Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.79% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently decreased by 1.49%, indicating that investor sentiment is improving.
  • Dividend Yield

    Y-mAbs Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Y-mAbs Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.79% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently decreased by 1.49%, indicating that investor sentiment is improving.
  • News Sentiment

    Y-mAbs Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 3 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Y-mAbs Therapeutics' insider trading history.
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha
Y mAbs Therapeutics News (YMAB) - Investing.com
Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
See More Headlines

YMAB Stock Analysis - Frequently Asked Questions

Y-mAbs Therapeutics' stock was trading at $7.83 at the start of the year. Since then, YMAB shares have decreased by 43.7% and is now trading at $4.41.
View the best growth stocks for 2025 here
.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative trailing twelve-month return on equity of 30.59%.
Read the conference call transcript
.

Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
7/01/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.60
High Stock Price Target
$26.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+241.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.67 million
Pretax Margin
-32.18%

Debt

Sales & Book Value

Annual Sales
$88.66 million
Price / Cash Flow
N/A
Book Value
$2.05 per share
Price / Book
2.23

Miscellaneous

Free Float
36,363,000
Market Cap
$207.17 million
Optionable
Optionable
Beta
0.52
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:YMAB) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners